The Pennsylvania-based company has specifically designed the investigational robotic-compatible OviTex IHR for use in laparoscopic and inguinal hernia repair
TELA Bio announces commercial launch of OviTex IHR in the US. (Credit: Piron Guillaume on Unsplash)
TELA Bio, a medical technology company delivering soft-tissue reconstruction solutions, has commercially launched the OviTex Inguinal Hernia Repair (IHR) Reinforced Tissue Matrix in the US.
The Pennsylvania-based firm has specifically designed the robotic-compatible OviTex IHR surgical mesh for use in laparoscopic and inguinal hernia repair.
The reinforced tissue matrix is offered in three configurations to give surgeons a range of alternatives to address specific patient, technique, or procedure-related aspects.
It comes in a three- or four-layer anatomically shaped device, or a three-layer rectangular device.
The medical technology company said that the trocar-compatibility of each configuration has been engineered to improve the usage of the devices in robotic and laparoscopic procedures.
OviTex IHR expands upon the OviTex portfolio, a next-generation reinforced biologic that reduces the permanent polymer footprint.
The OviTex range is made using layers of ovine (sheep) rumen interlaced with a little amount of polymer suture for extra strength.
TELA Bio president and CEO Antony Koblish said: “OviTex IHR, designed specifically for inguinal hernia repair and robotic-compatibility usage, is the next logical addition to our growing OviTex portfolio.
“The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials.
“With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”
Based on sales and internal data, OviTex has over eight years of clinical experience, more than 45,000 implantations, and 35 published or presented works showcasing its clinical efficacy in hernia repair, said TELA Bio.
The data contains an earlier retrospective study that investigated OviTex Core Permanent in a range of hernia repair procedures and indications.
The trial assessed 259 patients who had undergone robotic inguinal hernia TAPP repair utilising the ReBAR approach. The results showed an average follow-up of 1.5 years and a low recurrence rate of 1.2%.
Last month, the commercial-stage medical technology firm launched the LIQUIFIX FIX8 Laparoscopic and LIQUIFIX Precision Open Hernia Mesh Fixation Devices in the US.